Oncocyte CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $50.2 million for 2025, narrowing losses while advancing its core transplant diagnostics and securing significant capital for future growth.
Oncocyte Corporation's 2024 10-K filing reveals a year of strategic realignment, marked by increased operating losses and a focus on commercializing transplant diagnostic tests.
10-K: Oncocyte Corporation Details Share Structure, Warrants, and Regulatory Landscape in 10-K Filing
Oncocyte Corporation's 10-K filing provides a detailed overview of its common and preferred stock, outstanding warrants, and the regulatory environment it operates within.